Overview

Effectivness of Topical Tacrolimus Monotherapy in Patients With Vitiligo

Status:
Unknown status
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the effectiveness of Tacrolimus 0.03% ointment monotherapy in patients with vitiligo. Patients will be treated for 6 months and followed for 3 months after treatment. All types of vitiligo will be included.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sohag University
Treatments:
Cortisol succinate
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Tacrolimus